1
|
Jiang S, Liang M, Chen X, Yang R, Ding HX, Luo MJ, Huang H, Song XR, Xiao Q. TMSCl-Promoted Sulfonylation of Propargylic Alcohols with Sodium Sulfinates for the Construction of ( E)-1,3-Disulfonylpropenes and ( E)-1-Sulfonylpropenols. J Org Chem 2024. [PMID: 39395003 DOI: 10.1021/acs.joc.4c01829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2024]
Abstract
A direct and novel transformation of propargylic alcohols with sodium sulfinates for the regio- and stereoselective synthesis of (E)-1,3-disulfonylpropenes and (E)-1-sulfonylpropenols was successfully developed in the presence of TMSCl under mild conditions. The preliminary mechanistic experiments demonstrated that the reaction underwent an unprecedented dual nucleophilic substitution/radical addition process, in which sodium sulfinates were used not only as nucleophiles but also as a sulfonyl radical source.
Collapse
Affiliation(s)
- Shimin Jiang
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Meng Liang
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Xi Chen
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Ruchun Yang
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Hai-Xin Ding
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Mu-Jia Luo
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Haiyang Huang
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Xian-Rong Song
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| | - Qiang Xiao
- Jiangxi Province Key Laboratory of Organic Functional Molecules; Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi Province 330013, China
| |
Collapse
|
2
|
Bansode AH, Damuka N, Bashetti N, Gollapelli KK, Krizan I, Bhoopal B, Miller M, Jv SK, Whitlow CT, McClain D, Ma T, Jorgensen MJ, Solingapuram Sai KK. First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations. J Med Chem 2023; 66:9120-9129. [PMID: 37315328 PMCID: PMC10999001 DOI: 10.1021/acs.jmedchem.3c00720] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
G-protein-coupled receptor 119 (GPR119) has emerged as a promising target for treating type 2 diabetes mellitus. Activating GPR119 improves glucose homeostasis, while suppressing appetite and weight gain. Measuring GPR119 levels in vivo could significantly advance GPR119-based drug development strategies including target engagement, occupancy, and distribution studies. To date, no positron emission tomography (PET) ligands are available to image GPR119. In this paper, we report the synthesis, radiolabeling, and preliminary biological evaluations of a novel PET radiotracer [18F]KSS3 to image GPR119. PET imaging will provide information on GPR119 changes with diabetic glycemic loads and the efficacy of GPR119 agonists as antidiabetic drugs. Our results demonstrate [18F]KSS3's high radiochemical purity, specific activity, cellular uptake, and in vivo and ex vivo uptake in pancreas, liver, and gut regions, with high GPR119 expression. Cell pretreatment with nonradioactive KSS3, rodent PET imaging, biodistribution, and autoradiography studies showed significant blocking in the pancreas showing [18F]KSS3's high specificity.
Collapse
Affiliation(s)
- Avinash H Bansode
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Naresh Damuka
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Nagaraju Bashetti
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Vijayawada, 522302 Andhra Pradesh, India
| | - Krishna Kumar Gollapelli
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Ivan Krizan
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Bhuvanachandra Bhoopal
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Mack Miller
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Shanmukha Kumar Jv
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Vijayawada, 522302 Andhra Pradesh, India
| | - Christopher T Whitlow
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, United States
| | - Donald McClain
- Department of Endocrinology, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, United States
| | - Tao Ma
- Department of Internal Medicine-Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, United States
| | - Matthew J Jorgensen
- Department of Comparative Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, United States
| | | |
Collapse
|
3
|
Zhao H, Brånalt J, Perry M, Tyrchan C. The Role of Allylic Strain for Conformational Control in Medicinal Chemistry. J Med Chem 2023. [PMID: 37285219 DOI: 10.1021/acs.jmedchem.3c00446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
It is axiomatic in medicinal chemistry that optimization of the potency of a small molecule at a macromolecular target requires complementarity between the ligand and target. In order to minimize the conformational penalty on binding, both enthalpically and entropically, it is therefore preferred to have the ligand preorganized in the bound conformation. In this Perspective, we highlight the role of allylic strain in controlling conformational preferences. Allylic strain was originally described for carbon-based allylic systems, but the same principles apply to other types of structure with sp2 or pseudo-sp2 arrangements. These systems include benzylic (including heteroaryl methyl) positions, amides, N-aryl groups, aryl ethers, and nucleotides. We have derived torsion profiles from small molecule X-ray structures for these systems. Through multiple examples, we show how these effects have been applied in drug discovery and how they can be used prospectively to influence conformation in the design process.
Collapse
Affiliation(s)
- Hongtao Zhao
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Jonas Brånalt
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Matthew Perry
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Christian Tyrchan
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| |
Collapse
|
4
|
Bisht R, Haldar C, Hassan MMM, Hoque ME, Chaturvedi J, Chattopadhyay B. Metal-catalysed C-H bond activation and borylation. Chem Soc Rev 2022; 51:5042-5100. [PMID: 35635434 DOI: 10.1039/d1cs01012c] [Citation(s) in RCA: 83] [Impact Index Per Article: 41.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Transition metal-catalysed direct borylation of hydrocarbons via C-H bond activation has received a remarkable level of attention as a popular reaction in the synthesis of organoboron compounds owing to their synthetic versatility. While controlling the site-selectivity was one of the most challenging issues in these C-H borylation reactions, enormous efforts of several research groups proved instrumental in dealing with selectivity issues that presently reached an impressive level for both proximal and distal C-H bond borylation reactions. For example, in the case of ortho C-H bond borylation reactions, innovative methodologies have been developed either by the modification of the directing groups attached with the substrates or by creating new catalytic systems via the design of new ligand frameworks. Whereas meta and para selective C-H borylations remained a formidable challenge, numerous innovative concepts have been developed within a very short period of time by the development of new catalytic systems with the employment of various noncovalent interactions. Moreover, significant advancements have occurred for aliphatic C(sp3)-H borylations as well as enantioselective borylations. In this review article, we aim to discuss and summarize the different approaches and findings related to the development of directed proximal ortho, distal meta/para, aliphatic (racemic and enantioselective) borylation reactions since 2014. Additionally, considering the C-H borylation reaction as one of the most important mainstream reactions, various applications of this C-H borylation reaction toward the synthesis of natural products, therapeutics, and applications in materials chemistry will be summarized in the last part of this review article.
Collapse
Affiliation(s)
- Ranjana Bisht
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| | - Chabush Haldar
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| | - Mirja Md Mahamudul Hassan
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| | - Md Emdadul Hoque
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| | - Jagriti Chaturvedi
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| | - Buddhadeb Chattopadhyay
- Center of Bio-Medical Research, Division of Molecular Synthesis & Drug Discovery, SGPGIMS Campus, Raebareli Road, Lucknow 226014, Uttar Pradesh, India.
| |
Collapse
|
5
|
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorg Med Chem 2022; 56:116614. [DOI: 10.1016/j.bmc.2022.116614] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 12/15/2021] [Accepted: 01/06/2022] [Indexed: 12/19/2022]
|
6
|
Morimoto J, Miyamoto K, Ichikawa Y, Uchiyama M, Makishima M, Hashimoto Y, Ishikawa M. Improvement in aqueous solubility of achiral symmetric cyclofenil by modification to a chiral asymmetric analog. Sci Rep 2021; 11:12697. [PMID: 34135380 PMCID: PMC8209153 DOI: 10.1038/s41598-021-92028-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 06/03/2021] [Indexed: 11/10/2022] Open
Abstract
Decreasing the partition coefficient (LogP) by the introduction of a hydrophilic group is the conventional approach for improving the aqueous solubility of drug candidates, but is not always effective. Since melting point is related to aqueous solubility, we and other groups have developed alternative strategies to improve solubility by means of chemical modification to weaken intermolecular interaction in the solid state, thereby lowering the melting point and increasing the solubility. Here, we show that converting the symmetrical molecular structure of the clinically used estrogen receptor (ER) antagonist cyclofenil (1) into asymmetrical form by introducing an alkyl group enhances the aqueous solubility. Among the synthesized analogs, the chiral methylated analog (R)-4c shows the highest solubility, being 3.6-fold more soluble than 1 even though its hydrophobicity is increased by the methylation. Furthermore, (R)-4c also showed higher membrane permeability than 1, while retaining a comparable metabolic rate, and equivalent biological activity of the active forms (R)-13a to 2. Further validation of this strategy using lead compounds having symmetric structures is expected.
Collapse
Affiliation(s)
- Junki Morimoto
- Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan
| | - Kazunori Miyamoto
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Yuki Ichikawa
- Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan
| | - Masanobu Uchiyama
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.,Advanced Elements Chemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan
| | - Makoto Makishima
- Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan
| | - Yuichi Hashimoto
- Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan
| | - Minoru Ishikawa
- Graduate School of Life Sciences, Tohoku University, 2-1-1, Katahira, Aoba-ku, Sendai, Miyagi, 980-8577, Japan.
| |
Collapse
|
7
|
Fang T, Qiu J, Yang K, Song Q. Photo-induced weak base-catalyzed synthesis of α-haloboronates from vinylboronates and polyfluoroalkyl halides. Org Chem Front 2021. [DOI: 10.1039/d1qo00169h] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
An unprecedented strategy for the synthesis of sp2-α-haloboronates has been developed. Unique KOAc catalytic system, high synthetic application value of the product and no participation of metal constitute the notable features of this reaction.
Collapse
Affiliation(s)
- Tongchang Fang
- Key Laboratory of Molecule Synthesis and Function Discovery
- Fujian Province University
- College of Chemistry at Fuzhou University Fuzhou
- Fujian
- China
| | - Jian Qiu
- Key Laboratory of Molecule Synthesis and Function Discovery
- Fujian Province University
- College of Chemistry at Fuzhou University Fuzhou
- Fujian
- China
| | - Kai Yang
- Key Laboratory of Molecule Synthesis and Function Discovery
- Fujian Province University
- College of Chemistry at Fuzhou University Fuzhou
- Fujian
- China
| | - Qiuling Song
- Key Laboratory of Molecule Synthesis and Function Discovery
- Fujian Province University
- College of Chemistry at Fuzhou University Fuzhou
- Fujian
- China
| |
Collapse
|
8
|
Kerr WJ, Knox GJ, Reid M, Tuttle T, Bergare J, Bragg RA. Computationally-Guided Development of a Chelated NHC-P Iridium(I) Complex for the Directed Hydrogen Isotope Exchange of Aryl Sulfones. ACS Catal 2020; 10:11120-11126. [PMID: 33123410 PMCID: PMC7587147 DOI: 10.1021/acscatal.0c03031] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 08/27/2020] [Indexed: 02/05/2023]
Abstract
Herein, we report the rational, computationally-guided design of an iridium(I) catalyst system capable of enabling directed hydrogen isotope exchange (HIE) with the challenging sulfone directing group. Substrate binding energy was used as a parameter to guide rational ligand design via an in silico catalyst screen, resulting in a lead series of chelated iridium(I) NHC-phosphine complexes. Subsequent preparative studies show that the optimal catalyst system displays high levels of activity in HIE, and we demonstrate the labeling of a broad scope of substituted aryl sulfones. We also show that the activity of the catalyst is maintained at low pressures of deuterium gas and apply these conditions to tritium radiolabeling, including the expedient synthesis of a tritium-labeled drug molecule.
Collapse
Affiliation(s)
- William J. Kerr
- Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K
| | - Gary J. Knox
- Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K
| | - Marc Reid
- Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K
| | - Tell Tuttle
- Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K
| | - Jonas Bergare
- Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg SE-43183, Sweden
| | - Ryan A. Bragg
- Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K
| |
Collapse
|
9
|
Brock CP, Taylor R. Identifying and characterizing translationally modulated molecular crystal structures. ACTA CRYSTALLOGRAPHICA SECTION B, STRUCTURAL SCIENCE, CRYSTAL ENGINEERING AND MATERIALS 2020; 76:630-642. [PMID: 32831281 DOI: 10.1107/s2052520620007891] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 06/10/2020] [Indexed: 06/11/2023]
Abstract
Most structural (i.e. displacive) modulations make molecules independent that had been related by translation in a phase having a smaller or centered unit cell. In the modulated structure the independent molecules are differentiated by small translations, rotations, and/or conformational changes but an approximate translational relationship is normally retained. A program has been written to identify such pseudotranslations because they can be difficult to find by eye and because they combine with each other and with lattice translations in ways that can be confusing. To characterize the pseudotranslations the program calculates their fractional translational, orientational, and conformational components as well as several quality indicators. While many pseudotranslations are obvious, others are borderline; setting tolerances for identifying a pseudotranslation proved difficult. Defaults were chosen to reproduce experience-based judgment but they can be varied in the program input. The program was run for organic and for metallo-organic structures with R ≤ 0.075 in the 2019 release of the Cambridge Structural Database. The frequency of pseudotranslations increases with Z' and is approximately 50% for Z' > 4. Some structures were found in which an identified pseudotranslation cannot correspond to a modulation. These include structures in which some but not all of the molecules are related by pseudotranslations and structures in which pseudotranslations in different parts of the unit cell have different directions.
Collapse
Affiliation(s)
- Carolyn Pratt Brock
- Department of Chemistry, University of Kentucky, 505 Rose Street, Lexington, KY 40506-0055, United States
| | - Robin Taylor
- Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, United Kingdom
| |
Collapse
|
10
|
Babbs A, Berg A, Chatzopoulou M, Davies KE, Davies SG, Edwards B, Elsey DJ, Emer E, Guiraud S, Harriman S, Lecci C, Moir L, Peters D, Robinson N, Rowley JA, Russell AJ, Squire SE, Tinsley JM, Wilson FX, Wynne GM. 2-Arylbenzo[ d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy. J Med Chem 2020; 63:7880-7891. [PMID: 32551645 DOI: 10.1021/acs.jmedchem.0c00807] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD), which should be applicable to all patient populations. Following on from ezutromid, the first-generation utrophin modulator, we describe the development of a second generation of utrophin modulators, based on the bioisosteric replacement of the sulfone group with a phosphinate ester and substitution of the metabolically labile naphthalene with a haloaryl substituent. The improved physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties, further reflected in the enhanced pharmacokinetic profile of the most advanced compounds, 30 and 27, led to significantly better in vivo exposure compared to ezutromid and alleviation of the dystrophic phenotype in mdx mice. While 30 was found to have dose-limiting hepatotoxicity, 27 and its enantiomers exhibited limited off-target effects, resulting in a safe profile and highlighting their potential utility as next-generation utrophin modulators suitable for progression toward a future DMD therapy.
Collapse
Affiliation(s)
- Arran Babbs
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - Adam Berg
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - Maria Chatzopoulou
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K
| | - Kay E Davies
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - Stephen G Davies
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K
| | - Benjamin Edwards
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - David J Elsey
- Summit Therapeutics plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, U.K
| | - Enrico Emer
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K
| | - Simon Guiraud
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - Shawn Harriman
- Summit Therapeutics plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, U.K
| | - Cristina Lecci
- Evotec (UK) Ltd, 114 Innovation Dr, Milton Park, Milton, Abingdon OX14 4RZ, U.K
| | - Lee Moir
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - David Peters
- Summit Therapeutics plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, U.K
| | - Neil Robinson
- S.H.B. Enterprises Ltd, 55 Station Road, Beaconsfield HP19 1QL, U.K
| | - Jessica A Rowley
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K
| | - Angela J Russell
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.,Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3PQ, U.K
| | - Sarah E Squire
- MDUK Oxford Neuromuscular Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, U.K
| | - Jonathon M Tinsley
- Summit Therapeutics plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, U.K
| | - Francis X Wilson
- Summit Therapeutics plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, U.K
| | - Graham M Wynne
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K
| |
Collapse
|
11
|
Nieto A, Fernández-Vega V, Spicer TP, Sturchler E, Adhikari P, Kennedy N, Mandat S, Chase P, Scampavia L, Bannister T, Hodder P, McDonald PH. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Assay Drug Dev Technol 2019; 16:278-288. [PMID: 30019946 DOI: 10.1089/adt.2018.849] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
GPR119 drug discovery efforts in the pharmaceutical industry for the treatment of type 2 diabetes mellitus (T2DM) and obesity, were initiated based on its restricted distribution in pancreas and GI tract, and its possible role in glucose homeostasis. While a number of lead series have emerged, the pharmacological endpoints they provide have not been clear. In particular, many lead series have demonstrated loss of efficacy and significant toxic side effects. Thus, we sought to identify novel, potent, positive modulators of GPR119. In this study, we have successfully developed and optimized a high-throughput screening strategy to identify GPR119 modulators using a live cell assay format that utilizes a cyclic nucleotide-gated channel as a biosensor for cAMP production. Our high-throughput screening (HTS) approach is unique to that of previous HTS approaches targeting this receptor, as changes in cAMP were measured both in the presence and absence of an EC10 of the endogenous ligand, oleoylethanolamide, enabling detection of both agonists and potential allosteric modulators in a single assay. From these efforts, we have identified positive modulators of GPR119 with similar as well as unique scaffolds compared to existing compounds and similar as well as unique signaling properties. Our compounds will not only serve as novel molecular probes to better understand GPR119 pleiotropic signaling and the underlying physiological consequences of receptor activation, but are also well-suited for translation as potential therapeutic agents.
Collapse
Affiliation(s)
- Ainhoa Nieto
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | | | - Timothy P Spicer
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Emmanuel Sturchler
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Pramisha Adhikari
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Nicole Kennedy
- 2 Department of Chemistry, The Scripps Research Institute , Jupiter, Florida
| | - Sean Mandat
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Peter Chase
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Louis Scampavia
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Thomas Bannister
- 2 Department of Chemistry, The Scripps Research Institute , Jupiter, Florida
| | - Peter Hodder
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Patricia H McDonald
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| |
Collapse
|
12
|
Wang X, Liu WG, Tung CH, Wu LZ, Cong H. A Monophosphine Ligand Derived from Anthracene Photodimer: Synthetic Applications for Palladium-Catalyzed Coupling Reactions. Org Lett 2019; 21:8158-8163. [PMID: 31403303 DOI: 10.1021/acs.orglett.9b02414] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Herein, we present an air-stable dianthracenyl monophosphine ligand (diAnthPhos) which can be prepared in two steps from commercially available anthracene derivatives. The ligand exhibits excellent efficiency for palladium-catalyzed coupling reactions. In particular, Miyaura borylation of heterocycle-containing electrophiles can be facilitated employing the diAnthPhos ligand with a broad substrate scope and low catalyst loading. The valuable synthetic utility of the new ligand is further demonstrated by a one-pot Miyaura borylation/Suzuki coupling protocol for heteroaryl-containing substrates.
Collapse
Affiliation(s)
- Xin Wang
- Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry & School of Future Technology , University of Chinese Academy of Sciences, Chinese Academy of Sciences , Beijing , 100190 , China
| | - Wei-Gang Liu
- Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry & School of Future Technology , University of Chinese Academy of Sciences, Chinese Academy of Sciences , Beijing , 100190 , China
| | - Chen-Ho Tung
- Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry & School of Future Technology , University of Chinese Academy of Sciences, Chinese Academy of Sciences , Beijing , 100190 , China
| | - Li-Zhu Wu
- Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry & School of Future Technology , University of Chinese Academy of Sciences, Chinese Academy of Sciences , Beijing , 100190 , China
| | - Huan Cong
- Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry & School of Future Technology , University of Chinese Academy of Sciences, Chinese Academy of Sciences , Beijing , 100190 , China
| |
Collapse
|
13
|
Degorce SL, Bodnarchuk MS, Scott JS. Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a log D Lowering Twist. ACS Med Chem Lett 2019; 10:1198-1204. [PMID: 31417667 DOI: 10.1021/acsmedchemlett.9b00248] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 07/18/2019] [Indexed: 12/14/2022] Open
Abstract
We have conducted an analysis of azaspiro[3.3]heptanes used as replacements for morpholines, piperidines, and piperazines in a medicinal chemistry context. In most cases, introducing a spirocyclic center lowered the measured logD 7.4 of the corresponding molecules by as much as -1.0 relative to the more usual heterocycle. This may seem counterintuitive, as the net change in the molecule is the addition of a single carbon atom, but it may be rationalized in terms of increased basicity. An exception to this was found with N-linked 2-azaspiro[3.3]heptane, where logD 7.4 increased by as much as +0.5, consistent with the addition of carbon. During our investigation, we also concluded that azaspiro[3.3]heptanes are most likely not suitable bioisosteres for morpholines, piperidines, and piperazines, when not used as terminal groups, due to significant changes in their geometry.
Collapse
Affiliation(s)
- Sébastien L. Degorce
- Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - Michael S. Bodnarchuk
- Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| | - James S. Scott
- Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom
| |
Collapse
|
14
|
Taylor R, Wood PA. A Million Crystal Structures: The Whole Is Greater than the Sum of Its Parts. Chem Rev 2019; 119:9427-9477. [PMID: 31244003 DOI: 10.1021/acs.chemrev.9b00155] [Citation(s) in RCA: 134] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The founding in 1965 of what is now called the Cambridge Structural Database (CSD) has reaped dividends in numerous and diverse areas of chemical research. Each of the million or so crystal structures in the database was solved for its own particular reason, but collected together, the structures can be reused to address a multitude of new problems. In this Review, which is focused mainly on the last 10 years, we chronicle the contribution of the CSD to research into molecular geometries, molecular interactions, and molecular assemblies and demonstrate its value in the design of biologically active molecules and the solid forms in which they are delivered. Its potential in other commercially relevant areas is described, including gas storage and delivery, thin films, and (opto)electronics. The CSD also aids the solution of new crystal structures. Because no scientific instrument is without shortcomings, the limitations of CSD research are assessed. We emphasize the importance of maintaining database quality: notwithstanding the arrival of big data and machine learning, it remains perilous to ignore the principle of garbage in, garbage out. Finally, we explain why the CSD must evolve with the world around it to ensure it remains fit for purpose in the years ahead.
Collapse
Affiliation(s)
- Robin Taylor
- Cambridge Crystallographic Data Centre , 12 Union Road , Cambridge CB2 1EZ , United Kingdom
| | - Peter A Wood
- Cambridge Crystallographic Data Centre , 12 Union Road , Cambridge CB2 1EZ , United Kingdom
| |
Collapse
|
15
|
Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem 2018; 61:9889-9907. [PMID: 30346772 DOI: 10.1021/acs.jmedchem.8b01187] [Citation(s) in RCA: 181] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clinical response by increasing replication stress. Here we describe the development of the clinical candidate 2 (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. Compound 2 was developed improving aqueous solubility and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor 1 (AZ20). The clinical candidate 2 has favorable human PK suitable for once or twice daily dosing and achieves biologically effective exposure at moderate doses. Compound 2 is currently being tested in multiple phase I/II trials as an anticancer agent.
Collapse
Affiliation(s)
- Kevin M Foote
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - J Willem M Nissink
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Thomas McGuire
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Paul Turner
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Sylvie Guichard
- Bioscience, Oncology, IMED Biotech Unit , AstraZeneca , Chesterford Research Park , Little Chesterford, Cambridge CB10 1XL , U.K
| | - James W T Yates
- DMPK, Oncology, IMED Biotech Unit , AstraZeneca , Chesterford Research Park , Little Chesterford, Cambridge CB10 1XL , U.K
| | - Alan Lau
- Bioscience, Oncology, IMED Biotech Unit , AstraZeneca , Chesterford Research Park , Little Chesterford, Cambridge CB10 1XL , U.K
| | - Kevin Blades
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Dan Heathcote
- Discovery Sciences, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Rajesh Odedra
- Bioscience, Oncology, IMED Biotech Unit , AstraZeneca , Chesterford Research Park , Little Chesterford, Cambridge CB10 1XL , U.K
| | - Gary Wilkinson
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Zena Wilson
- Bioscience, Oncology, IMED Biotech Unit , AstraZeneca , Chesterford Research Park , Little Chesterford, Cambridge CB10 1XL , U.K
| | - Christine M Wood
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| | - Philip J Jewsbury
- Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, 310 Milton Road , Milton, Cambridge CB4 0WG , U.K
| |
Collapse
|
16
|
Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes. Bioorg Med Chem 2018; 26:4080-4087. [DOI: 10.1016/j.bmc.2018.06.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 06/25/2018] [Accepted: 06/26/2018] [Indexed: 12/30/2022]
|
17
|
Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: A review. Eur J Med Chem 2018; 152:436-488. [PMID: 29751237 DOI: 10.1016/j.ejmech.2018.04.061] [Citation(s) in RCA: 185] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 04/17/2018] [Accepted: 04/30/2018] [Indexed: 12/22/2022]
Abstract
Diabetes mellitus is a medical condition characterized by the body's loss of control over blood sugar. The frequency of diagnosed cases and consequential increases in medical costs makes it a rapidly growing chronic disease that threatens human health worldwide. In addition, its unnerving statistical projections are perilous to both the economy of the nation and man's life expectancy. Type-I and type-II diabetes are the two clinical forms of diabetes mellitus. Type-II diabetes mellitus (T2DM) is illustrated by the abnormality of glucose homeostasis in the body, resulting in hyperglycemia. Although significant research attention has been devoted to the development of diabetes regimens, which demonstrates success in lowering blood glucose levels, their efficacies are unsustainable due to undesirable side effects such as weight gain and hypoglycemia. Over the years, heterocyclic scaffolds have been the basis of anti-diabetic chemotherapies; hence, in this review we consolidate the use of bioactive scaffolds, which have been evaluated for their biological response as inhibitors against their respective anti-diabetic molecular targets over the past five years (2012-2017). Our investigation reveals a diverse target set which includes; protein tyrosine phosphatase 1 B (PTP1B), dipeptidly peptidase-4 (DPP-4), free fatty acid receptors 1 (FFAR1), G protein-coupled receptors (GPCR), peroxisome proliferator activated receptor-γ (PPARγ), sodium glucose co-transporter-2 (SGLT2), α-glucosidase, aldose reductase, glycogen phosphorylase (GP), fructose-1,6-bisphosphatase (FBPase), glucagon receptor (GCGr) and phosphoenolpyruvate carboxykinase (PEPCK). This review offers a medium on which future drug design and development toward diabetes management may be modelled (i.e. optimization via structural derivatization), as many of the drug candidates highlighted show promise as an effective anti-diabetic chemotherapy.
Collapse
Affiliation(s)
- Nagaraju Kerru
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa
| | - Ashona Singh-Pillay
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa.
| | - Paul Awolade
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa
| | - Parvesh Singh
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa.
| |
Collapse
|
18
|
Practical application of ligand efficiency metrics in lead optimisation. Bioorg Med Chem 2018; 26:3006-3015. [PMID: 29655612 DOI: 10.1016/j.bmc.2018.04.004] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 03/30/2018] [Accepted: 04/02/2018] [Indexed: 11/21/2022]
Abstract
The use of composite metrics that normalise biological potency values in relation to markers of physicochemical properties, such as size or lipophilicity, has gained a significant amount of traction with many medicinal chemists in recent years. However, there is no consensus on best practice in the area and their application has attracted some criticism. Here we present our approach to their application in lead optimisation projects, provide an objective discussion of the principles we consider important and illustrate how our use of lipophilic ligand efficiency enabled the progression of a number of our successful drug discovery projects. We derive, from this and some recent literature highlights, a set of heuristic guidelines for lipophilicity based optimisation that we believe are generally applicable across chemical series and protein targets.
Collapse
|
19
|
Novel 3 H -[1,2,3]triazolo[4,5- c ]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships. Bioorg Med Chem 2017; 25:4339-4354. [DOI: 10.1016/j.bmc.2017.06.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 06/10/2017] [Accepted: 06/12/2017] [Indexed: 12/29/2022]
|
20
|
Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity. Mol Divers 2017; 21:637-654. [DOI: 10.1007/s11030-017-9755-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2016] [Accepted: 05/27/2017] [Indexed: 01/31/2023]
|
21
|
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Bioorg Med Chem Lett 2017; 27:2515-2519. [PMID: 28408218 DOI: 10.1016/j.bmcl.2017.03.092] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 03/19/2017] [Accepted: 03/31/2017] [Indexed: 11/23/2022]
Abstract
A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50 values to endogenous lipid oleoylethanolamide (OEA). Analogs with 2-fluoro substitution in the aryl ring showed more potent GPR119 activation than those without fluorine. Especially compound 27m synthesized from endo-azabicyclic alcohol was observed to have the best EC50 value (1.2nM) and quite good agonistic activity (112.2% max) as a full agonist.
Collapse
|
22
|
Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, Szewczyk JW, Kang L, Chicchi G, Ehrhardt A, Woods A, Seo T, Woods M, van Heek M, Dingley KH, Pang J, Salituro GM, Powell J, Terebetski JL, Hornak V, Campeau LC, Orr RK, Ujjainwalla F, Miller M, Stamford A, Wood HB, Kowalski T, Nargund RP, Edmondson SD. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 2017; 27:1124-1128. [DOI: 10.1016/j.bmcl.2017.01.091] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 01/27/2017] [Indexed: 01/05/2023]
|
23
|
Groom CR, Cole JC. The use of small-molecule structures to complement protein-ligand crystal structures in drug discovery. Acta Crystallogr D Struct Biol 2017; 73:240-245. [PMID: 28291759 PMCID: PMC5349436 DOI: 10.1107/s2059798317000675] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 01/13/2017] [Indexed: 11/10/2022] Open
Abstract
Many ligand-discovery stories tell of the use of structures of protein-ligand complexes, but the contribution of structural chemistry is such a core part of finding and improving ligands that it is often overlooked. More than 800 000 crystal structures are available to the community through the Cambridge Structural Database (CSD). Individually, these structures can be of tremendous value and the collection of crystal structures is even more helpful. This article provides examples of how small-molecule crystal structures have been used to complement those of protein-ligand complexes to address challenges ranging from affinity, selectivity and bioavailability though to solubility.
Collapse
Affiliation(s)
- Colin R. Groom
- Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, England
| | - Jason C. Cole
- Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, England
| |
Collapse
|
24
|
In silico approaches to explore structure of new GPR 119 agonists for treatment of type 2 diabetes mellitus. Med Chem Res 2017. [DOI: 10.1007/s00044-017-1808-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Fang Y, Yang Z, Gundeti S, Lee J, Park H. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists. Bioorg Med Chem 2017; 25:254-260. [DOI: 10.1016/j.bmc.2016.10.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 10/24/2016] [Accepted: 10/26/2016] [Indexed: 10/20/2022]
|
26
|
Hintermann S, Guntermann C, Mattes H, Carcache DA, Wagner J, Vulpetti A, Billich A, Dawson J, Kaupmann K, Kallen J, Stringer R, Orain D. Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists. ChemMedChem 2016; 11:2640-2648. [PMID: 27902884 DOI: 10.1002/cmdc.201600500] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 11/09/2016] [Indexed: 11/07/2022]
Abstract
Retinoic-acid-related orphan receptor γt (RORγt) is a key transcription factor implicated in the production of pro-inflammatory Th17 cytokines, which drive a number of autoimmune diseases. Despite diverse chemical series having been reported, combining high potency with a good physicochemical profile has been a very challenging task in the RORγt inhibitor field. Based on available chemical structures and incorporating in-house knowledge, a new series of triazolo- and imidazopyridine RORγt inverse agonists was designed. In addition, replacement of the terminal cyclopentylamide metabolic soft spot by five-membered heterocycles was investigated. From our efforts, we identified an optimal 6,7,8-substituted imidazo[1,2-a]pyridine core system and a 5-tert-butyl-1,2,4-oxadiazole as cyclopentylamide replacement leading to compounds 10 ((S)-N-(8-((4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-methylpyrimidine-5-carboxamide) and 33 ((S)-N-(8-((4-(5-(tert-butyl)-1,2,4-oxadiazol-3-yl)-3-methylpiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-methylpyrimidine-5-carboxamide). Both derivatives showed good pharmacological potencies in biochemical and cell-based assays combined with excellent physicochemical properties, including low to medium plasma protein binding across species. Finally, 10 and 33 were shown to be active in a rodent pharmacokinetic/pharmacodynamic (PK/PD) model after oral gavage at 15 mg kg-1 , lowering IL-17 cytokine production in ex vivo antigen recall assays.
Collapse
Affiliation(s)
- Samuel Hintermann
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Christine Guntermann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Henri Mattes
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - David A Carcache
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Juergen Wagner
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Anna Vulpetti
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Andreas Billich
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Janet Dawson
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Klemens Kaupmann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Joerg Kallen
- CPC, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Rowan Stringer
- MAP, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - David Orain
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| |
Collapse
|
27
|
Hassing HA, Engelstoft MS, Sichlau RM, Madsen AN, Rehfeld JF, Pedersen J, Jones RM, Holst JJ, Schwartz TW, Rosenkilde MM, Hansen HS. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor. Biofactors 2016; 42:665-673. [PMID: 27297962 DOI: 10.1002/biof.1303] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Revised: 05/01/2016] [Accepted: 05/18/2016] [Indexed: 12/26/2022]
Abstract
The intestinal G protein-coupled receptor GPR119 is a novel metabolic target involving glucagon-like peptide-1 (GLP-1)-derived insulin-regulated glucose homeostasis. Endogenous and diet-derived lipids, including N-acylethanolamines and 2-monoacylglycerols (2-MAG) activate GPR119. The purpose of this work is to evaluate whether 2-oleoyl glycerol (2-OG) improves glucose tolerance through GPR119, using wild type (WT) and GPR 119 knock out (KO) mice. We here show that GPR119 is essential for 2-OG-mediated release of GLP-1 and CCK from GLUTag cells, since a GPR119 specific antagonist completely abolished the hormone release. Similarly, in isolated primary colonic crypt cultures from WT mice, GPR119 was required for 2-OG-stimulated GLP-1 release while there was no response in crypts from KO mice. In vivo, gavage with 2-oleyl glyceryl ether ((2-OG ether), a stable 2-OG analog with a potency of 5.3 µM for GPR119 with respect to cAMP formation as compared to 2.3 µM for 2-OG), significantly (P < 0.05) improved glucose clearance in WT littermates, but not in GPR119 KO mice. Finally, deletion of GPR119 in mice resulted in lower glucagon levels, whereas the levels of insulin and GIP were unchanged. In the present study we show that 2-OG stimulates GLP-1 secretion through GPR119 activation in vitro, and that fat-derived 2-MAGs are potent candidates for mediating fat-induced GLP-1 release through GPR119 in vivo. © 2016 BioFactors, 42(6):665-673, 2016.
Collapse
Affiliation(s)
- H A Hassing
- Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - M S Engelstoft
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - R M Sichlau
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - A N Madsen
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - J F Rehfeld
- Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej, Copenhagen, Denmark
| | - J Pedersen
- Department of Biomedical Science, Endocrinology Research Section, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - R M Jones
- Arena Pharmaceutical Inc, San Diego, CA, 92121, USA
| | - J J Holst
- Department of Biomedical Science, Endocrinology Research Section, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Translational Physiology, Novo Nordisk Foundation Center for Metabolic Research, Panum Institute, Blegdamsvej 3, Copenhagen, Denmark
| | - T W Schwartz
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - M M Rosenkilde
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - H S Hansen
- Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark
| |
Collapse
|
28
|
Genovino J, Sames D, Hamann LG, Touré BB. Die Erschließung von Wirkstoffmetaboliten durch übergangsmetallkatalysierte C-H-Oxidation: die Leber als Inspiration für die Synthese. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201602644] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Julien Genovino
- Pfizer Inc.; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic, and Endocrine Diseases (CVMED); 558 Eastern Point Road Groton CT 06340 USA
| | - Dalibor Sames
- Columbia University; Department of Chemistry and Neurotechnology Center; 3000 Broadway MC3101 New York NY 10027 USA
| | - Lawrence G. Hamann
- Novartis Institutes for Biomedical Sciences (NIBR), Global Discovery Chemistry (GDC); 181 Massachusetts Avenue Cambridge MA 02139 USA
| | - B. Barry Touré
- Novartis Institutes for Biomedical Sciences (NIBR), Global Discovery Chemistry (GDC); 100 Technology Square Cambridge MA 02139 USA
| |
Collapse
|
29
|
Genovino J, Sames D, Hamann LG, Touré BB. Accessing Drug Metabolites via Transition-Metal Catalyzed C-H Oxidation: The Liver as Synthetic Inspiration. Angew Chem Int Ed Engl 2016; 55:14218-14238. [PMID: 27723189 DOI: 10.1002/anie.201602644] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 06/08/2016] [Indexed: 11/07/2022]
Abstract
Can classical and modern chemical C-H oxidation reactions complement biotransformation in the synthesis of drug metabolites? We have surveyed the literature in an effort to try to answer this important question of major practical significance in the pharmaceutical industry. Drug metabolites are required throughout all phases of the drug discovery and development process; however, their synthesis is still an unsolved problem. This Review, not intended to be comprehensive or historical, highlights relevant applications of chemical C-H oxidation reactions, electrochemistry and microfluidic technologies to drug templates in order to access drug metabolites, and also highlights promising reactions to this end. Where possible or appropriate, the contrast with biotransformation is drawn. In doing so, we have tried to identify gaps where they exist in the hope to spur further activity in this very important research area.
Collapse
Affiliation(s)
- Julien Genovino
- Pfizer Inc., Worldwide Medicinal Chemistry, Cardiovascular, Metabolic, and Endocrine Diseases (CVMED), 558 Eastern Point Road, Groton, CT, 06340, USA
| | - Dalibor Sames
- Columbia University, Department of Chemistry and Neurotechnology Center, 3000 Broadway MC3101, New York, NY, 10027, USA
| | - Lawrence G Hamann
- Novartis Institutes for Biomedical Sciences (NIBR), Global Discovery Chemistry (GDC), 181 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - B Barry Touré
- Novartis Institutes for Biomedical Sciences (NIBR), Global Discovery Chemistry (GDC), 100 Technology Square, Cambridge, MA, 02139, USA.
| |
Collapse
|
30
|
Lu K, Duan L, Xu B, Yin W, Wu D, Zhao Y, Gong P. Facile synthesis of 3-amino-5-aryl-1,2,4-oxadiazoles via PIDA-mediated intramolecular oxidative cyclization. RSC Adv 2016. [DOI: 10.1039/c6ra08871f] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Advantages: ambient condition and simple procedure. Additive and metal free method. Up to 25 examples and 79% yield. Wide functional groups tolerance.
Collapse
Affiliation(s)
- Kuan Lu
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Liancheng Duan
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Boxuan Xu
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Weile Yin
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Di Wu
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Yanfang Zhao
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| | - Ping Gong
- Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
- Ministry of Education
- Shenyang 110016
- PR China
| |
Collapse
|
31
|
Khojastehnezhad A, Eshghi H, Moeinpour F, Bakavoli M, Izadyar M, Tajabadi J. Density functional theory study of the regio‐ and stereoselectivity of 1,3-dipolar cycloaddition reactions between 2-ethylthio-4-phenyl-1-azetin and some substituted nitrile oxides. Struct Chem 2015. [DOI: 10.1007/s11224-015-0703-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Ritter K, Buning C, Halland N, Pöverlein C, Schwink L. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. J Med Chem 2015; 59:3579-92. [PMID: 26512410 DOI: 10.1021/acs.jmedchem.5b01198] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In this Perspective, recent advances and challenges in the development of GPR119 agonists as new oral antidiabetic drugs will be discussed. Such agonists are expected to exhibit a low risk to induce hypoglycemia as well as to have a beneficial impact on body weight. Many pharmaceutical companies have been active in the search for GPR119 agonists, making it a highly competitive area in the industrial environment. Several GPR119 agonists have been entered into clinical studies, but many have failed either in phase I or II and none has progressed beyond phase II. Herein we describe the strategies chosen by the different medicinal chemistry teams in academia and the pharmaceutical industry to improve potency, physicochemical properties, pharmacokinetics, and the safety profile of GPR119 agonists in the discovery phase in order to improve the odds for successful development.
Collapse
Affiliation(s)
- Kurt Ritter
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christian Buning
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Nis Halland
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christoph Pöverlein
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Lothar Schwink
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| |
Collapse
|
33
|
Hothersall JD, Bussey CE, Brown AJ, Scott JS, Dale I, Rawlins P. Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur J Pharmacol 2015; 762:430-42. [PMID: 26101059 DOI: 10.1016/j.ejphar.2015.06.031] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 06/15/2015] [Accepted: 06/16/2015] [Indexed: 12/16/2022]
Abstract
G protein-coupled receptor 119 (GPR119) is involved in regulating metabolic homoeostasis, with GPR119 agonists targeted for the treatment of type-2 diabetes and obesity. Using the endogenous agonist oleoylethanolamide and a number of small molecule synthetic agonists we have investigated the temporal dynamics of receptor signalling. Using both a dynamic luminescence biosensor-based assay and an endpoint cAMP accumulation assay we show that agonist-driven desensitization is not a major regulatory mechanism for GPR119 despite robust activation responses, regardless of the agonist used. Temporal analysis of the cAMP responses demonstrated sustained signalling resistant to washout for some, but not all of the agonists tested. Further analysis indicated that the sustained effects of one synthetic agonist AR-231,453 were consistent with a role for slow dissociation kinetics. In contrast, the sustained responses to MBX-2982 and AZ1 appeared to involve membrane deposition. We also detect wash-resistant responses to AR-231,453 at the level of physiologically relevant responses in an endogenous expression system (GLP-1 secretion in GLUTag cells). In conclusion, our findings indicate that in a recombinant expression system GPR119 activation is sustained, with little evidence of pronounced receptor desensitization, and for some ligands persistent agonist responses continue despite removal of excess agonist. This provides novel understanding of the temporal responses profiles of potential drug candidates targetting GPR119, and highlights the importance of carefully examining the the mechanisms through which GPCRs generate sustained responses.
Collapse
Affiliation(s)
| | | | - Alastair J Brown
- AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK; Heptares Therapeutics Limited, Welwyn Garden City AL7 3AX, UK
| | - James S Scott
- AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK
| | - Ian Dale
- AstraZeneca, Cambridge Science Park, Cambridge CB4 0WG, UK
| | - Philip Rawlins
- AstraZeneca, Cambridge Science Park, Cambridge CB4 0WG, UK
| |
Collapse
|
34
|
Yamamoto E, Ukigai S, Ito H. Boryl substitution of functionalized aryl-, heteroaryl- and alkenyl halides with silylborane and an alkoxy base: expanded scope and mechanistic studies. Chem Sci 2015; 6:2943-2951. [PMID: 29308171 PMCID: PMC5656038 DOI: 10.1039/c5sc00384a] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Accepted: 03/02/2015] [Indexed: 01/01/2023] Open
Abstract
A transition-metal-free method has been developed for the boryl substitution of functionalized aryl-, heteroaryl- and alkenyl halides with a silylborane in the presence of an alkali-metal alkoxide. The base-mediated boryl substitution of organohalides with a silylborane was recently reported to provide the corresponding borylated products in good to high yields, and exhibit good functional group compatibility and high tolerance to steric hindrance. In this study, the scope of this transformation has been extended significantly to include a wide variety of functionalized aryl-, heteroaryl- and alkenyl halides. In particular, the boryl substitution of (E)- and (Z)-alkenyl halides proceeded smoothly to afford the corresponding alkenyl boronates in good to high yields with retention of the configuration using modified reaction conditions. The results of the mechanistic studies suggest that this boryl substitution proceeds via a carbanion-mediated mechanism.
Collapse
Affiliation(s)
- Eiji Yamamoto
- Division of Chemical Process Engineering and Frontier Chemistry Center , Faculty of Engineering , Hokkaido University , Sapporo 060-8628 , Japan .
| | - Satoshi Ukigai
- Division of Chemical Process Engineering and Frontier Chemistry Center , Faculty of Engineering , Hokkaido University , Sapporo 060-8628 , Japan .
| | - Hajime Ito
- Division of Chemical Process Engineering and Frontier Chemistry Center , Faculty of Engineering , Hokkaido University , Sapporo 060-8628 , Japan .
| |
Collapse
|
35
|
Docherty R, Pencheva K, Abramov YA. Low solubility in drug development: de-convoluting the relative importance of solvation and crystal packing. ACTA ACUST UNITED AC 2015; 67:847-56. [PMID: 25880016 DOI: 10.1111/jphp.12393] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 01/06/2015] [Indexed: 12/12/2022]
Abstract
OBJECTIVES An increasing trend towards low solubility is a major issue for drug development as formulation of low solubility compounds can be problematic. This paper presents a model which de-convolutes the solubility of pharmaceutical compounds into solvation and packing properties with the intention to understand the solubility limiting features. METHODS The Cambridge Crystallographic Database was the source of structural information. Lattice energies were calculated via force-field based approaches using Materials Studio. The solvation energies were calculated applying quantum chemistry models using Cosmotherm software. KEY FINDINGS The solubilities of 54 drug-like compounds were mapped onto a solvation energy/crystal packing grid. Four quadrants were identified were different balances of solvation and packing were defining the solubility. A version of the model was developed which allows for the calculation of the two features even in absence of crystal structure. CONCLUSION Although there are significant number of in-silico models, it has been proven very difficult to predict aqueous solubility accurately. Therefore, we have taken a different approach where the solubility is not predicted directly but is de-convoluted into two constituent features.
Collapse
Affiliation(s)
- Robert Docherty
- Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, Kent, UK
| | | | - Yuriy A Abramov
- Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, Kent, UK
| |
Collapse
|
36
|
Fresneau N, Dumas N, Tournier BB, Fossey C, Ballandonne C, Lesnard A, Millet P, Charnay Y, Cailly T, Bouillon JP, Fabis F. Design of a serotonin 4 receptor radiotracer with decreased lipophilicity for single photon emission computed tomography. Eur J Med Chem 2015; 94:386-96. [PMID: 25778994 DOI: 10.1016/j.ejmech.2015.03.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 03/05/2015] [Accepted: 03/06/2015] [Indexed: 10/23/2022]
Abstract
With the aim to develop a suitable radiotracer for the brain imaging of the serotonin 4 receptor subtype (5-HT4R) using single photon emission computed tomography (SPECT), we synthesized and evaluated a library of di- and triazaphenanthridines with lipophilicity values which were in the range expected to favour brain penetration, and which demonstrated specific binding to the target of interest. Adding additional nitrogen atoms to previously described phenanthridine ligands exhibiting a high unspecific binding, we were able to design a radioiodinated compound [(125)I]14. This compound exhibited a binding affinity value of 0.094 nM toward human 5-HT4R and a high selectivity over other serotonin receptor subtypes (5-HTR). In vivo SPECT imaging studies and competition experiments demonstrated that the decreased lipophilicity (in comparison with our previously reported compounds 4 and 5) allowed a more specific labelling of the 5-HT4R brain-containing regions.
Collapse
Affiliation(s)
- Nathalie Fresneau
- Normandie Univ., COBRA, UMR 6014 et FR 3038, Univ. Rouen, INSA Rouen, CNRS, 1 Rue Tesnière, F-76821 Mont-Saint-Aignan Cedex, France
| | - Noé Dumas
- Hôpitaux Universitaires de Genève, Département de Santé Mentale et de Psychiatrie, Service de Psychiatrie Générale, Unité des Biomarqueurs de Vulnérabilité, Chemin du Petit-Bel-Air, 2, CH-1225 Genève, Switzerland
| | - Benjamin B Tournier
- Hôpitaux Universitaires de Genève, Département de Santé Mentale et de Psychiatrie, Service de Psychiatrie Générale, Unité des Biomarqueurs de Vulnérabilité, Chemin du Petit-Bel-Air, 2, CH-1225 Genève, Switzerland
| | - Christine Fossey
- Normandie Univ., Université de Caen Basse-Normandie, CERMN (EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE), UFR des Sciences Pharmaceutiques, Bd Becquerel, F-14032 Caen, France
| | - Céline Ballandonne
- Normandie Univ., Université de Caen Basse-Normandie, CERMN (EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE), UFR des Sciences Pharmaceutiques, Bd Becquerel, F-14032 Caen, France
| | - Aurélien Lesnard
- Normandie Univ., Université de Caen Basse-Normandie, CERMN (EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE), UFR des Sciences Pharmaceutiques, Bd Becquerel, F-14032 Caen, France
| | - Philippe Millet
- Hôpitaux Universitaires de Genève, Département de Santé Mentale et de Psychiatrie, Service de Psychiatrie Générale, Unité des Biomarqueurs de Vulnérabilité, Chemin du Petit-Bel-Air, 2, CH-1225 Genève, Switzerland
| | - Yves Charnay
- Hôpitaux Universitaires de Genève, Département de Santé Mentale et de Psychiatrie, Service de Psychiatrie Générale, Unité des Biomarqueurs de Vulnérabilité, Chemin du Petit-Bel-Air, 2, CH-1225 Genève, Switzerland
| | - Thomas Cailly
- Normandie Univ., Université de Caen Basse-Normandie, CERMN (EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE), UFR des Sciences Pharmaceutiques, Bd Becquerel, F-14032 Caen, France
| | - Jean-Philippe Bouillon
- Normandie Univ., COBRA, UMR 6014 et FR 3038, Univ. Rouen, INSA Rouen, CNRS, 1 Rue Tesnière, F-76821 Mont-Saint-Aignan Cedex, France.
| | - Frédéric Fabis
- Normandie Univ., Université de Caen Basse-Normandie, CERMN (EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE), UFR des Sciences Pharmaceutiques, Bd Becquerel, F-14032 Caen, France.
| |
Collapse
|
37
|
Cui B, Yu J, Yu FC, Li YM, Chang KJ, Shen Y. Synthesis of (1R,4R)-2,5-diazabicyclo[2.2.1]heptane derivatives by an epimerization–lactamization cascade reaction. RSC Adv 2015. [DOI: 10.1039/c4ra13611j] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
An epimerization–lactamization cascade of functionalized (2S,4R)-4-aminoproline methyl esters is developed and applied in synthesizing (1R,4R)-2,5-diazabicyclo[2.2.1]heptane (DBH) derivatives.
Collapse
Affiliation(s)
- Benqiang Cui
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| | - Jie Yu
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| | - Fu-Chao Yu
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| | - Ya-Min Li
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| | - Kwen-Jen Chang
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| | - Yuehai Shen
- Faculty of Life Sciences and Technology
- Kunming University of Science and Technology
- Kunming
- China
| |
Collapse
|
38
|
Scott JS, Bowker SS, Brocklehurst KJ, Brown HS, Clarke DS, Easter A, Ertan A, Goldberg K, Hudson JA, Kavanagh S, Laber D, Leach AG, MacFaul PA, Martin EA, McKerrecher D, Schofield P, Svensson PH, Teague J. Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists. J Med Chem 2014; 57:8984-98. [DOI: 10.1021/jm5011012] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- James S. Scott
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Suzanne S. Bowker
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Katy J. Brocklehurst
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Hayley S. Brown
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David S. Clarke
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Alison Easter
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Anne Ertan
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Kristin Goldberg
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Julian A. Hudson
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Stefan Kavanagh
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David Laber
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Andrew G. Leach
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Philip A. MacFaul
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Elizabeth A. Martin
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Darren McKerrecher
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Paul Schofield
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Per H. Svensson
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Joanne Teague
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| |
Collapse
|
39
|
Ozaki S, Nakagawa Y, Shirai O, Kano K. Substituent Effect on the Thermodynamic Solubility of Structural Analogs: Relative Contribution of Crystal Packing and Hydration. J Pharm Sci 2014; 103:3524-3531. [DOI: 10.1002/jps.24139] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Accepted: 08/07/2014] [Indexed: 12/28/2022]
|
40
|
Chen J, Pu Y, Pei H, He L, Fu S, Chen L. Synthesis and biological evaluation of tert-butyl-5-methylpyrimidin-piperazine derivatives as anti-obesity agents. Arch Pharm (Weinheim) 2014; 347:908-22. [PMID: 25220533 DOI: 10.1002/ardp.201400227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Revised: 07/09/2014] [Accepted: 07/11/2014] [Indexed: 02/05/2023]
Abstract
A series of tert-butyl-5-methylpyrimidin-piperazine derivatives were synthesized and their anti-obesity activities were evaluated. Compounds 4g and 5j were found to have significant effects in down-regulating the triglyceride level of 3T3-L1 adipocytes. 5j exhibited remarkable therapeutic effects on the diet-induced obesity (DIO) mouse model at 20 mg kg(-1) day(-1) for 4 weeks by decreasing the weights of body, liver, and fat. 5j also regulated serum biomarkers to appropriate ranges, exerted therapeutic activity of steatosis in liver tissue and ameliorated the obese-related symptoms. In addition, 5j significantly decreased the blood glucose levels in oral glucose tolerance tests and improved the insulin sensitivity in insulin tolerance tests. These results suggest that 5j could be a candidate for obesity treatment.
Collapse
Affiliation(s)
- Jinying Chen
- State Key Laboratory of Biotherapy, West China Hospital, West China Medical, Sichuan University, Chengdu, P. R. China
| | | | | | | | | | | |
Collapse
|
41
|
General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor. Tetrahedron 2014. [DOI: 10.1016/j.tet.2014.06.120] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
42
|
Takeuchi T, Oishi S, Kaneda M, Ohno H, Nakamura S, Nakanishi I, Yamane M, Sawada JI, Asai A, Fujii N. Kinesin spindle protein inhibitors with diaryl amine scaffolds: crystal packing analysis for improved aqueous solubility. ACS Med Chem Lett 2014; 5:566-71. [PMID: 24900881 DOI: 10.1021/ml500016j] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 03/10/2014] [Indexed: 01/31/2023] Open
Abstract
Diaryl amine derivatives have been designed and synthesized as novel kinesin spindle protein (KSP) inhibitors based on planar carbazole-type KSP inhibitors with poor aqueous solubility. The new generation of inhibitors was found to show comparable inhibitory activity and high selectivity for KSP, and this was accompanied with improved solubility. Kinetic analysis and molecular modeling studies suggested that these inhibitors work in an ATP-competitive manner via binding to the secondary allosteric site formed by α4 and α6 helices of KSP. Comparative structural investigations on a series of compounds revealed that the higher solubility of diaryl amine-type inhibitors was attributed to fewer van der Waals interactions in the crystal packing and the hydrogen-bond acceptor nitrogen of the aniline moiety for favorable solvation.
Collapse
Affiliation(s)
- Tomoki Takeuchi
- Graduate
School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - Shinya Oishi
- Graduate
School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - Masato Kaneda
- Graduate
School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - Hiroaki Ohno
- Graduate
School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - Shinya Nakamura
- Faculty
of Pharmacy, Kinki University, 3-4-1 Kowakae, Higashi-osaka 577-8502, Japan
| | - Isao Nakanishi
- Faculty
of Pharmacy, Kinki University, 3-4-1 Kowakae, Higashi-osaka 577-8502, Japan
| | - Masayoshi Yamane
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan
| | - Jun-ichi Sawada
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan
| | - Akira Asai
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan
| | - Nobutaka Fujii
- Graduate
School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| |
Collapse
|
43
|
Larsen MA, Hartwig JF. Iridium-catalyzed C-H borylation of heteroarenes: scope, regioselectivity, application to late-stage functionalization, and mechanism. J Am Chem Soc 2014; 136:4287-99. [PMID: 24506058 DOI: 10.1021/ja412563e] [Citation(s) in RCA: 260] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
A study on the iridium-catalyzed C-H borylation of heteroarenes is reported. Several heteroarenes containing multiple heteroatoms were found to be amenable to C-H borylation catalyzed by the combination of an iridium(I) precursor and tetramethylphenanthroline. The investigations of the scope of the reaction led to the development of powerful rules for predicting the regioselectivity of borylation, foremost of which is that borylation occurs distal to nitrogen atoms. One-pot functionalizations are reported of the heteroaryl boronate esters formed in situ, demonstrating the usefulness of the reported methodology for the synthesis of complex heteroaryl structures. Application of this methodology to the synthesis and late-stage functionalization of biologically active compounds is also demonstrated. Mechanistic studies show that basic heteroarenes can bind to the catalyst and alter the resting state from the olefin-bound complex observed during arene borylation to a species containing a bound heteroarene, leading to catalyst deactivation. Studies on the origins of the observed regioselectivity show that borylation occurs distal to N-H bonds due to rapid N-H borylation, creating an unfavorable steric environment for borylation adjacent to these bonds. Computational studies and mechanistic studies show that the lack of observable borylation of C-H bonds adjacent to basic nitrogen is not the result of coordination to a bulky Lewis acid prior to C-H activation, but the combination of a higher-energy pathway for the borylation of these bonds relative to other C-H bonds and the instability of the products formed from borylation adjacent to basic nitrogen.
Collapse
Affiliation(s)
- Matthew A Larsen
- Department of Chemistry, University of California , Berkeley, California 94720, United States
| | | |
Collapse
|
44
|
Targeting GPR119 for the Potential Treatment of Type 2 Diabetes Mellitus. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2014; 121:95-131. [DOI: 10.1016/b978-0-12-800101-1.00004-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
45
|
Scott JS, Brocklehurst KJ, Brown HS, Clarke DS, Coe H, Groombridge SD, Laber D, MacFaul PA, McKerrecher D, Schofield P. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. Bioorg Med Chem Lett 2013; 23:3175-9. [PMID: 23628336 DOI: 10.1016/j.bmcl.2013.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 03/28/2013] [Accepted: 04/02/2013] [Indexed: 02/07/2023]
Abstract
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors.
Collapse
Affiliation(s)
- James S Scott
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Futatsugi K, Mascitti V, Guimarães CR, Morishita N, Cai C, DeNinno MP, Gao H, Hamilton MD, Hank R, Harris AR, Kung DW, Lavergne SY, Lefker BA, Lopaze MG, McClure KF, Munchhof MJ, Preville C, Robinson RP, Wright SW, Bonin PD, Cornelius P, Chen Y, Kalgutkar AS. From partial to full agonism: Identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor. Bioorg Med Chem Lett 2013. [DOI: 10.1016/j.bmcl.2012.10.119] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
47
|
Leach AG. Tactics to Avoid Inhibition of Cytochrome P450s. TOPICS IN MEDICINAL CHEMISTRY 2013. [DOI: 10.1007/7355_2013_25] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
|
48
|
Darout E, Robinson RP, McClure KF, Corbett M, Li B, Shavnya A, Andrews MP, Jones CS, Li Q, Minich ML, Mascitti V, Guimarães CRW, Munchhof MJ, Bahnck KB, Cai C, Price DA, Liras S, Bonin PD, Cornelius P, Wang R, Bagdasarian V, Sobota CP, Hornby S, Masterson VM, Joseph RM, Kalgutkar AS, Chen Y. Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119. J Med Chem 2012; 56:301-19. [DOI: 10.1021/jm301626p] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Etzer Darout
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Ralph P. Robinson
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Kim F. McClure
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Matthew Corbett
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Bryan Li
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Andrei Shavnya
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Melissa P. Andrews
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Christopher S. Jones
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Qifang, Li
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Martha L. Minich
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Vincent Mascitti
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cristiano R. W. Guimarães
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Michael J. Munchhof
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Kevin B. Bahnck
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cuiman Cai
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - David A. Price
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Spiros Liras
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Paul D. Bonin
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Peter Cornelius
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Ruduan Wang
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Victoria Bagdasarian
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Colleen P. Sobota
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Sam Hornby
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Victoria M. Masterson
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Reena M. Joseph
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Yue Chen
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
49
|
Wellenzohn B, Lessel U, Beller A, Isambert T, Hoenke C, Nosse B. Identification of New Potent GPR119 Agonists by Combining Virtual Screening and Combinatorial Chemistry. J Med Chem 2012; 55:11031-41. [DOI: 10.1021/jm301549a] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Bernd Wellenzohn
- Research Germany/Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| | - Uta Lessel
- Research Germany/Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| | - Andreas Beller
- Research Germany/Medicinal Chemistry/Combinatorial Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| | - Timo Isambert
- Research Germany/Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| | - Christoph Hoenke
- Research Germany/Medicinal Chemistry/Combinatorial Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| | - Bernd Nosse
- Research Germany/Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany
| |
Collapse
|
50
|
Crawford JJ, Kenny PW, Bowyer J, Cook CR, Finlayson JE, Heyes C, Highton AJ, Hudson JA, Jestel A, Krapp S, Martin S, MacFaul PA, McDermott BP, McGuire TM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Dossetter AG. Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors. J Med Chem 2012; 55:8827-37. [DOI: 10.1021/jm301119s] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- James J. Crawford
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Peter W. Kenny
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Jonathan Bowyer
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Calum R. Cook
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Jonathan E. Finlayson
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Christine Heyes
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Adrian J. Highton
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Julian A. Hudson
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Anja Jestel
- Proteros Biostructures, Am Klopferspitz 19, D-82152 Martinsried,
Germany
| | - Stephan Krapp
- Proteros Biostructures, Am Klopferspitz 19, D-82152 Martinsried,
Germany
| | - Scott Martin
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Philip A. MacFaul
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Benjamin P. McDermott
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Thomas M. McGuire
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Andrew D. Morley
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Jeffrey J. Morris
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Ken M. Page
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Lyn Rosenbrier Ribeiro
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Helen Sawney
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Stefan Steinbacher
- Proteros Biostructures, Am Klopferspitz 19, D-82152 Martinsried,
Germany
| | - Caroline Smith
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Alexander G. Dossetter
- AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| |
Collapse
|